Quote:

---

I think the hold has more to do with safety data aggregation that was lacking to properly inform physicians reviewing drug for prescribing purposes

---

I think it has to do with the aggregation of data between the mono and combo trials. If Amarex can't even put headers on data then combining basic data from two trials was sure to stump them.